Amphastar Pharmaceuticals, Inc. (AMPH)
Automate Your Wheel Strategy on AMPH
With Tiblio's Option Bot, you can configure your own wheel strategy including AMPH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AMPH
- Rev/Share 15.2865
- Book/Share 15.7697
- PB 1.6018
- Debt/Equity 0.8686
- CurrentRatio 2.9538
- ROIC 0.1112
- MktCap 1190733666.0
- FreeCF/Share 3.1533
- PFCF 7.9262
- PE 8.497
- Debt/Assets 0.4012
- DivYield 0
- ROE 0.1937
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | AMPH | JP Morgan | Overweight | Neutral | -- | $30 | May 12, 2025 |
| Downgrade | AMPH | Piper Sandler | Overweight | Neutral | $66 | $36 | Feb. 4, 2025 |
News
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Published: May 22, 2025 by: Accesswire
Sentiment: Neutral
RANCHO CUCAMONGA, CA / ACCESS Newswire / May 22, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Jacob Liawatidewi, EVP of Corporate Administration, will be participating in an Analyst-Moderated fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5th, 2025, at 2:00 pm ET. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.
Read More
Amphastar Pharmaceuticals to Present at the 2025 Bank of America Health Care Conference
Published: May 09, 2025 by: Accesswire
Sentiment: Neutral
RANCHO CUCAMONGA, CA / ACCESS Newswire / May 9, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be participating in an Analyst-Moderated fireside chat at the 2025 Bank of America Health Care Conference on Wednesday, May 14th, 2025, at 1:40 pm PT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.
Read More
Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metrics
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Amphastar Pharmaceuticals Inc. (AMPH) Q1 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH ) Q1 2025 Results Conference Call May 7, 2025 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Corporate Communications William Peters - Chief Financial Officer & Executive Vice President of Finance Tony Marrs - Executive Vice President of Regulatory Affairs & Clinical Operations Conference Call Participants David Amsellem - Piper Sandler Cerena Chen - Wells Fargo Jason Gerberry - Bank of America Ekaterina Knyazkova - JPMorgan Operator Greetings and welcome to the Amphastar Pharmaceuticals First Quarter Earnings Call. At this time, all participants are in a listen-only mode.
Read More
Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $1.04 per share a year ago.
Read More
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025
Published: April 30, 2025 by: Accesswire
Sentiment: Neutral
RANCHO CUCAMONGA, CA / ACCESS Newswire / April 30, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2025 ended March 31, 2025, after the market closes on Wednesday, May 7th, 2025, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
Read More
Amphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
Published: April 03, 2025 by: Accesswire
Sentiment: Neutral
RANCHO CUCAMONGA, CA / ACCESS Newswire / April 3, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be participating in an Analyst-Moderated fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9th, 2025, at 1:30 pm ET. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.
Read More
New Strong Sell Stocks for March 24th
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Negative
AVNS, AIRS and AMPH have been added to the Zacks Rank #5 (Strong Sell) List on March 24, 2025.
Read More
Specialty Pharma Amphastar Stock Falls On Lower Than Expected Q4 Earnings, Analyst Sees Competitive Headwinds
Published: February 28, 2025 by: Benzinga
Sentiment: Negative
On Thursday, Amphastar Pharmaceuticals Inc. AMPH reported fourth-quarter adjusted EPS of 92 cents, up from 88 cents a year ago, but missing the consensus of 94 cents.
Read More
Amphastar: Earnings Miss, Margins Drop
Published: February 28, 2025 by: The Motley Fool
Sentiment: Negative
Amphastar Pharmaceuticals posted modest earnings growth but fell short of market expectations in its latest quarterly results.
Read More
Amphastar Pharmaceuticals Inc. (AMPH) Q4 2024 Earnings Call Transcript
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Corporate Communications William Peters - Chief Financial Officer & Executive Vice President of Finance Tony Marrs - Executive Vice President of Regulatory Affairs & Clinical Operations Conference Call Participants Jason Gerberry - Bank of America Cerena Chen - Wells Fargo Ekaterina Knyazkova - JPMorgan David Amsellem - Piper Sandler Serge Belanger - Needham & Company Operator Greetings and welcome to the Amphastar Pharmaceuticals Fourth Quarter Earnings Call. At this time, all participants are in a …
Read More
Amphastar (AMPH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Amphastar (AMPH) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Investors who Lost Money on Amphastar Pharmaceuticals, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - AMPH
Published: February 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug.
Read More
Amphastar Pharmaceuticals: A Gradual Strategy
Published: February 19, 2025 by: Seeking Alpha
Sentiment: Positive
Amphastar Pharmaceuticals has a growth model based on organic growth and acquisitions, though competition and patent expirations pose risks. Financially, Amphastar has a strong revenue trend but faces potential growth slowdowns, especially in 2025. A fair value estimate derived from a DCF model and backed by a comparison with peers is $43.24, which suggests a 40% upside.
Read More
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Amphastar Pharmaceuticals, Inc. (AMPH)
Published: February 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug.
Read More
About Amphastar Pharmaceuticals, Inc. (AMPH)
- IPO Date 2014-06-25
- Website https://www.amphastar.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Dr. Yongfeng Zhang Ph.D.
- Employees 2028